StreetInsider.com News Articles

Form 10-K Cardio Diagnostics Holdi For: Dec 31

Fri, 13 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260313/26160631.html

Form 10-K Cardio Diagnostics Holdi For: Dec 31

Fri, 13 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260313/26160631.html

Form 8-K Cardio Diagnostics Holdi For: Feb 19

Thu, 19 Feb 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260219/26026344.html

Form 8-K Cardio Diagnostics Holdi For: Feb 19

Thu, 19 Feb 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260219/26026344.html

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.

The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.

Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
The updated release reads:
CARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
The updated release reads:
CARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
The updated release reads:
CARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Tue, 17 Feb 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
The updated release reads:
CARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

Wed, 07 Jan 2026 06:25:00 -0400

Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories

Form 4 Cardio Diagnostics Holdi For: Dec 31 Filed by: Fung Peter K

Tue, 06 Jan 2026 14:20:00 -0400
si-local-file:///var/storage/secattach/20260106/25812432.html

Form 4 Cardio Diagnostics Holdi For: Dec 31 Filed by: Fung Peter K

Tue, 06 Jan 2026 14:20:00 -0400
si-local-file:///var/storage/secattach/20260106/25812432.html

Form 4 Cardio Diagnostics Holdi For: Dec 31 Filed by: Betts Wendy J

Tue, 06 Jan 2026 14:17:00 -0400
si-local-file:///var/storage/secattach/20260106/25812418.html

Form 4 Cardio Diagnostics Holdi For: Dec 31 Filed by: Betts Wendy J

Tue, 06 Jan 2026 14:17:00 -0400
si-local-file:///var/storage/secattach/20260106/25812418.html

Form 4 Cardio Diagnostics Holdi For: Dec 31 Filed by: Intrater James

Tue, 06 Jan 2026 14:14:00 -0400
si-local-file:///var/storage/secattach/20260106/25812405.html